Many will remember 2003 as the year of biomarker hype and hope, but as a several researchers in the field told ProteoMonitor this month, biomarkers were not the only show in town — nor are they the only story to look for in 2004. Fourier-transform mass specs, an increased emphasis on quantitation and post-translational modifications, as well as the mass production of antibodies also featured prominently in 2003, and are slated to continue to play a central role in 2004.

FT-MS: here today, still here at ASMS?

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.